US FDA grants fast track designation to EDDC's antibody─drug conjugate EBC─129 to treat pancreatic ductal adenocarcinoma
The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for EBC-129 for the treatment of pancreatic …